Intraocular Povidone Iodine During Pars Plana Vitrectomy for Severe and Atypical Endophthalmitis

Ophthalmic Surg Lasers Imaging Retina. 2021 Sep;52(9):485-490. doi: 10.3928/23258160-20210820-01. Epub 2021 Sep 1.

Abstract

Background and objective: To describe the experience and clinical outcomes of povidone iodine (PI) infusion in the setting of pars plana vitrectomy for the treatment of endophthalmitis.

Materials and methods: This was a retrospective case series of 12 patients with clinical and/or culture evidence of endophthalmitis requiring pars plana vitrectomy with 0.025% PI used in vitreous irrigation solution during vitrectomy. The primary endpoint was clinical resolution of the infection. Secondary endpoints included visual recovery, need for repeat surgery, and ocular toxicity RESULTS: There were 11 eyes that showed clinical or culture evidence of resolution of infection postoperatively (91.7%); 10 eyes had improvement in vision postoperatively (83.3%). Overall uncorrected visual acuity improved from 20/5321 (2.43 ± 0.58 logMAR) to 20/375 (1.27 ± 1.05 logMAR) (P = .0003). No clinical evidence of ocular toxicity or unexplained vision loss due to PI was observed.

Conclusions: PI infusion during pars plana vitrectomy for endophthalmitis appears safe and led to excellent post-surgical results in a traditionally high-risk cohort. [Ophthalmic Surg Lasers Imaging Retina. 2021;52:485-490.].

MeSH terms

  • Endophthalmitis* / etiology
  • Endophthalmitis* / surgery
  • Humans
  • Povidone-Iodine*
  • Retrospective Studies
  • Visual Acuity
  • Vitrectomy

Substances

  • Povidone-Iodine